WO2003013557A1 - Utilisation d'extraits de larves de mouches pour traiter des plaies - Google Patents

Utilisation d'extraits de larves de mouches pour traiter des plaies Download PDF

Info

Publication number
WO2003013557A1
WO2003013557A1 PCT/EP2002/008497 EP0208497W WO03013557A1 WO 2003013557 A1 WO2003013557 A1 WO 2003013557A1 EP 0208497 W EP0208497 W EP 0208497W WO 03013557 A1 WO03013557 A1 WO 03013557A1
Authority
WO
WIPO (PCT)
Prior art keywords
fly larvae
fly
extract according
larvae extract
homogenization
Prior art date
Application number
PCT/EP2002/008497
Other languages
German (de)
English (en)
Other versions
WO2003013557A8 (fr
Inventor
Karl-Heinz Nietsch
Rainer Pooth
Heinz Mehlhorn
T. Ruzicka
Helger Stege
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10138303A external-priority patent/DE10138303A1/de
Priority claimed from DE10149153A external-priority patent/DE10149153A1/de
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Priority to JP2003518564A priority Critical patent/JP2005501078A/ja
Priority to IL16027402A priority patent/IL160274A0/xx
Priority to EP02794527A priority patent/EP1434591A1/fr
Priority to CA002456814A priority patent/CA2456814A1/fr
Priority to MXPA04000298A priority patent/MXPA04000298A/es
Publication of WO2003013557A1 publication Critical patent/WO2003013557A1/fr
Publication of WO2003013557A8 publication Critical patent/WO2003013557A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the invention relates to the topical application of fly larvae extracts of various species, which belong for example to the genera Sarcophaga or Lucilia, for the treatment of superficial or deep chronic and acute wounds of any origin.
  • Wound healing is a complex process in which multiple target cells and target structures must interlock in an orderly sequence of processes. These processes take place regardless of the type of wound (chronic / acute), while the duration of individual phases is variable. There are generally three main phases, the exudative phase, the proliferative phase and the epithelialization or repair phase.
  • the proliferative phase begins due to the migration of fibroblasts and vascular endothelial cells.
  • the cell content increases massively due to the immigrated fibroblasts and endothelial cells.
  • cytokines and growth factors are released, which in turn stimulate new vascularization and cell proliferation.
  • a matrix conversion takes place in this phase. This takes place through the formation and conversion of collagen type III into collagen type I. This creates a well-capillaryized, macrophage, fibroblast and mast cell-rich granulation tissue.
  • the epithelization and repair phase follows this proliferative phase. In this final phase there is wound contraction and migration of marginal keratinocytes into the wound. Neoangiogenesis and capillary density decrease. The collagen content, however, increases. This process is relevant for the mechanical strength of the resulting scar tissue.
  • Wound healing disorders These occur in a variety of immunologically related diseases, varicose veins, arterial occlusive disease, after infections and, for example, diabetes mellitus. Measures to promote wound healing serve the accelerated or regular sequence of the processes described above. Wound cleansing procedures, in addition to granulation-promoting processes, are to be mentioned here. Epithelization can also be promoted by modern "wound dressings".
  • One of the main causes of delayed wound healing is the lack of formation of granulation tissue. This can either be caused by reduced endogenous wound debridement, or it can result from infections, circulatory disorders, immunological diseases an excessive formation of cell and tissue detritus.
  • wound cleansing measures are used.
  • the aim of cleaning is to create a clean wound bed.
  • ointment residues and crusts must first be removed and any existing necrosis removed. The latter is done either surgically with a sharp spoon (curettage) or with tweezers and scissors.
  • enzymatic ointments that preferentially break down denatured protein. They contain enzymes such as trypsin, chymotrypsin, enzymes from bovine material such as pancreatic enzymes, or collagenase, fibrolysin, streptokinase or calf blood dialysates.
  • regular disinfection is carried out, for example with potassium permanganate or with Rivanol® baths.
  • Disinfectant measures can also be carried out with preparations containing silver or iodine
  • the enzymatic preparations often show only limited effectiveness on the patient.
  • the dosage of the enzyme is often very low and the half-life of the known enzyme preparations is 6 to 12 hours. For this reason, daily, even repeated dressing changes are necessary.
  • Some of the preparations are combination preparations with topical antibiotics.
  • the disadvantage of combination products is the risk of epicutaneous sensitization. Almost 60-70% of patients with chronic leg ulcers suffer from one or more sensitizations based on ointments or other components of topical externals.
  • maggots larvae of the species Lucilia sericata on wounds. This therapy is based on ancient folk medicine and partly on war medicine findings and observations about the contamination of war injuries with fly maggots.
  • the maggots of this species feed exclusively on necrotic tissue. This material is, as it were, digested by secretion of saliva and only then absorbed by the maggot.
  • the maggots of L. sericata do not actively chew or bite. This ensures that the maggots cannot penetrate other parts of the body or unaffected body cavities.
  • the treatment with the maggot shows very high therapeutic effectiveness. However, the current treatment method is extremely complicated, expensive and requires a high logistical effort. For use in humans, the maggots should be grown under controlled conditions.
  • Patent application WO 01/31033 describes a protein secreted to the outside by living maggots of the species Lucilia sericata, for which a wound healing property is assumed. However, physiological experiments on wounds that could support this assumption are missing.
  • the application WO 01/31033 describes the isolation of a very small amount of the secreted protein, but an economical method for obtaining marketable amounts of protein would still have to be developed.
  • an oily formulation of a powder from dried fly larvae in oil is known, which is or has been used for wound treatment in China (Yang Zheng .: China Science: House fly yields medicine, expert say. In: Inter Press Service; 03.09. 1997, 97: 314231 NLDB).
  • a disadvantage of the oil is that it can cause allergies as a side effect.
  • fly larvae extracts according to the invention represent a clear one
  • maggot therapy in terms of application and dosage. It is also possible to use the extracts in modern, hydrophilic wound dressings. The therapy can be better controlled by standardizing the manufacturing process. As a finished product, the fly larvae extracts have a continuous performance that does not depend on the maggot development cycle.
  • the invention therefore relates to fly larvae extracts obtainable from fly larvae, the fly larvae first being cooled and then homogenized and the homogenate obtained finally being freed from undissolved components of the fly larvae.
  • an extraction medium can be added before homogenization.
  • the extraction medium contains water or is an organic solvent. Furthermore, the soluble components can be preserved or applied topically to the wounds immediately. When applied topically, the extract according to the invention has a wound healing effect in the case of superficial, deep, chronic or acute wounds of any origin.
  • Suitable fly larvae come, for example, from the genera Sarcophaga, Lucilia, Musca, Calliphora and Stomoxys. Mixtures of Fly larvae from the genera mentioned are used in the process according to the invention.
  • Suitable species from the genera mentioned are, for example, Lucilia sericata, Lucilia caesar, Lucilia cuprina, Sarcophaga carnaria, Sarcophaga agyrostoma, Musca domestica, Calliphora erythrocephala, Calliphora vicina or Stomoxys caicitrans.
  • the genera Sarcophaga and Lucilia are, for example, ubiquitous and a person skilled in the art can easily find these insects, for example by laying out fresh meat.
  • the fly larvae extracts according to the invention are produced, for example, by keeping eggs or larvae of the species Lucilia sericata and / or Sarcophaga carnaria on fresh meat.
  • the larvae grow and thrive on the meat and are harvested shortly before entering the pupation stage. It is advantageous to harvest the larvae from day 5 to day 8 after hatching from the egg.
  • the larvae are killed and processed about 5 to 8 days after the larvae hatch from the egg, but each time before pupation.
  • the killed larvae are cooled before and during the further processing to the fly larvae extract.
  • Possible cooling temperatures are temperatures below 0 ° C, i.e. in the frozen state, for example at temperatures from 0 ° C to - 80 ° C. However, it is also possible to work at temperatures from 0 ° C. to 15 ° C., preferably from 0 ° C. to 10 ° C., in particular from 2 ° C. to 6 ° C.
  • the larvae can also be frozen for homogenization or for further processing, or crushed and homogenized in the frozen state.
  • the larvae are first made largely sterile on the outside and freed of possible secretions and excretions (SE) that could adhere to the body of the female. This is done by several washing steps in aseptic solutions in decreasing concentration. Sterilized NaCI solution is used in the last washing steps, thereby ensuring that the larvae are largely sterile. Further all secretions and excretions of the maggots are washed off and the maggots are preserved on ice.
  • SE secretions and excretions
  • the larvae are homogenized, for example, by mechanical comminution or ultrasound.
  • the fly larvae can be homogenized as such or preferably with the addition of an extraction medium.
  • 0.1 ml to 500 ml of extraction solution preferably 0.5 ml to 100 ml, very preferably 1 to 5 ml of extraction solution, are added per gram of wet weight of fly larvae.
  • Sterile extraction solutions for example aqua purificata, physiological salt solutions, buffers, electrolyte, sugar or protein solutions and aqueous emulsions and organic solvents are particularly suitable.
  • the addition of extraction media can also be dispensed with entirely and only the liquid components of the maggots can be squeezed.
  • the extract can also be prepared in such a way that the active ingredients are precipitated by adding organic solvents and then extracted.
  • the homogenate is separated into solid and soluble constituents, for example by filtration or centrifugation.
  • the fly larvae extracts may be preserved by freezing or freeze-drying.
  • other known agents for stabilizing active molecules can be used, for example protease inhibitors, trehalose, ectoin or buffers.
  • the extract is filtered, for example sterile filtered, using a filter which has a pore diameter of 0.1 ⁇ m to 0.4 ⁇ m.
  • the extract is aliquoted and frozen in liquid nitrogen. Permanent storage takes place at a temperature of around -21 ° C to -80 ° C or in liquid nitrogen.
  • the sterile-filtered extracts obtained can also be lyophilized.
  • the extracts according to the invention can also be further purified or fractionated using conventional purification methods, such as by selective precipitation steps or chromatographic or electrophoretic processes.
  • the invention also relates to pharmaceuticals, characterized by an effective content of the fly larvae extracts according to the invention together with a pharmaceutically suitable and physiologically compatible carrier, additive and / or other active substances and auxiliaries.
  • fly larvae extracts according to the invention are suitable for the therapy of superficial or deep chronic and acute wounds of any origin.
  • chronic and acute wounds of any genesis is understood to mean, for example, wounds such as surgical wounds which are intended to heal secondarily or unintentionally, cuts, stab wounds, abrasions, bites, burns or bullet wounds, and other wounds which are not can be treated primarily with surgical sutures or primary wound closure.
  • acute wounds means all wounds which cannot be healed primarily by superinfection and all wounds whose manifestation is 4 weeks and less.
  • Chronic wounds are all injuries associated with the loss of epithelial integrity that are manifest for more than 4 weeks.
  • the invention also relates to a method for producing a medicament, which is characterized in that the fly larvae extracts according to the invention are brought into a suitable dosage form with a pharmaceutically suitable and physiologically tolerable carrier and, if appropriate, other suitable active ingredients, additives or auxiliaries.
  • the invention also relates to the use of the fly larvae extracts according to the invention for the production of medicaments for the therapy of superficial or deep chronic and acute wounds of any origin.
  • the medicaments according to the invention are generally applied topically.
  • Suitable pharmaceutical compositions for topical application on the skin are preferably in the form of a solution, suspension, powder, liposomal formulations, gel, lotion, paste, spray or aerosol.
  • Polyethylene glycols, alcohols and combinations of two or more of these substances can also be used as carriers. The list can in no way be interpreted as restrictive.
  • the fly larvae extracts according to the invention are present in a concentration of 0.1% by weight to 100% by weight of the composition, for example from 1.0% by weight to 60% by weight.
  • Suitable pharmaceutical compositions for transdermal applications can be presented as individual patches which are suitable for long-term close contact with the patient's epidermis.
  • Such plasters suitably contain the fly larvae extracts according to the invention in an optionally buffered aqueous solution, dissolved and / or dispersed in an adhesive or dispersed in a polymer.
  • a suitable active ingredient concentration is from about 0.1% by weight to 75% by weight, preferably from 1% by weight to 70% by weight.
  • the active ingredient can be released by electrotransport or iontophoresis, as described, for example, in Pharmaceutical Research, 2 (6): 318 (1986).
  • the fly larvae extracts according to the invention can also be applied to the wound by wound dressings made of gauze, from alginates, from hydrocolloid materials, foams and silicone dressings which have been coated, soaked or treated with these fly larvae extracts and are therefore able to place the fly larvae extracts in or on the Deliver the wound or wound surface.
  • suitable solid or galenical forms of preparation are, for example, granules, powders, solutions, suspensions, emulsions or drops, as well as preparations with a protracted release of active ingredient, in the preparation of which conventional auxiliaries or carriers are used.
  • fly larvae extracts according to the invention can also be used in pharmaceutical preparations which contain the fly larvae extracts in inactive form and which are then applied to or on the wound and are activated by adding specific substances.
  • Simple examples are the use of a powder or of lyophilisates, which are dissolved with physiological solutions (e.g. 0.9% NaCl). If the stability is sufficient, the pharmaceutical preparation can also be a solution.
  • the appropriate pharmaceutical compositions are applied after mechanical wound cleaning.
  • Mechanical wound cleaning is carried out, for example, by bathing or flushing the wound with Ringer's lactate.
  • the wound is optionally covered by means of hydrocolloid wound dressings or by means of a self-adhesive surgical film. Dressing changes with new administration of the fly larvae extracts according to the invention take place daily. example 1
  • Larvae of the species Lucilia sericata and / or Sarcophaga carnaria were kept on fresh and not or only slightly contaminated horse meat and harvested shortly before entering the pupation stage.
  • the larvae were largely sterile.
  • the larvae were then decapitated, i.e. the front third was separated from the rest of the larval body. Both larval parts were immediately preserved separately on ice in a carrier medium.
  • the larvae were then homogenized. This was done in several steps by mechanical comminution and homogenization using ultrasound. Attention was paid to constant cooling at about 4 "Celsius.
  • the extract was sterile filtered (Millipore filter). In the last processing step, the extract was aliquoted and frozen in liquid nitrogen. The permanent storage took place at about -21 ° C to -80 ° C.
  • the fly larvae extract prepared according to Example 1 made from equal parts by weight maggots and physiological saline solution, was applied with 2 ml each.
  • the ulcers are of venous origin and were influenced by the use of painkillers in the sense of vasculitis.
  • the treatment began with systemic administration of steroids and simultaneous local application of the fly larvae extract prepared according to Example 1 to promote debridement. It became comparative Fibrolan® ointment and aqueous solutions of the extract according to the invention are used.
  • Fibrolan® ointment is a preparation on the red list containing plasmin from bovine plasma and deoxyribonuclease from bovine pancreas. In the case of the extracts from the larvae, a distinction was made between the extracts from the front part and the rear part of the larvae. The assignment was made at the beginning of the therapy and was maintained over the entire duration of the treatment.
  • the fly larvae extract prepared according to Example 1 was used in an 87-year-old patient who had been suffering from ulcera curum vasculitic genesis for years. No further ulcerations occurred after systemic steroid use. Local therapy was compared with Fibrolan® ointment and the extracts according to the invention.
  • the ulcer that was treated with the extracts according to the invention initially showed a stronger necrotic and fibrinous coverage than the comparative ulcer that was treated with Fibrolan® ointment.
  • After 8 days of treatment there was a significantly faster debridement of the ulcer, which was treated with the extracts according to the invention, in comparison with the Fibrolan® ointment.
  • the success of the treatment was documented using color photographs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'application topique d'extraits de larves de mouches, obtenus à partir de larves de mouches qui sont tuées, transformées en extraits à des conditions de refroidissement en milieu aqueux ou dans des solvants, et dépourvues des composés non dissouts. Différents types d'extraits de larves de mouches sont conçus pour traiter des plaies superficielles ou des plaies profondes, chroniques et aiguës, quelle qu'en soit l'origine. Les extraits de larves de mouches présentant un pouvoir de guérison des plaies peuvent par exemple être produits à partir de larves de mouches du genre Sarcophaga ou Lucilia.
PCT/EP2002/008497 2001-08-10 2002-07-31 Utilisation d'extraits de larves de mouches pour traiter des plaies WO2003013557A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003518564A JP2005501078A (ja) 2001-08-10 2002-07-31 創傷治療のためのハエ幼虫の抽出物の使用
IL16027402A IL160274A0 (en) 2001-08-10 2002-07-31 The use of fly larval extracts for wound treatment
EP02794527A EP1434591A1 (fr) 2001-08-10 2002-07-31 Utilisation d'extraits de larves de mouches pour traiter des plaies
CA002456814A CA2456814A1 (fr) 2001-08-10 2002-07-31 Utilisation d'extraits de larves de mouches pour traiter des plaies
MXPA04000298A MXPA04000298A (es) 2001-08-10 2002-07-31 El uso de extractos de larvas de mosca para tratamiento de heridas.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10138303A DE10138303A1 (de) 2001-08-10 2001-08-10 Verwendung von Enzymisolaten aus Fliegenlarven zur Wundbehandlung
DE10138303.7 2001-08-10
DE10149153.0 2001-10-04
DE10149153A DE10149153A1 (de) 2001-10-04 2001-10-04 Verwendung von Enzymisolaten aus Fliegenlarven zur Wundbehandlung

Publications (2)

Publication Number Publication Date
WO2003013557A1 true WO2003013557A1 (fr) 2003-02-20
WO2003013557A8 WO2003013557A8 (fr) 2004-02-26

Family

ID=26009873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008497 WO2003013557A1 (fr) 2001-08-10 2002-07-31 Utilisation d'extraits de larves de mouches pour traiter des plaies

Country Status (6)

Country Link
EP (1) EP1434591A1 (fr)
JP (1) JP2005501078A (fr)
CA (1) CA2456814A1 (fr)
IL (1) IL160274A0 (fr)
MX (1) MXPA04000298A (fr)
WO (1) WO2003013557A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075654A2 (fr) * 2002-03-09 2003-09-18 The Secretary Of State For Defence Traitement de surfaces peuplees de bacteries
DE102005061246A1 (de) * 2005-12-20 2007-06-28 Alpha-Biocare Gmbh Präparate mit niedermolekularen Substanzen aus Dipteren zur Behandlung von Wunden
CN102008003A (zh) * 2010-12-14 2011-04-13 韦秀凤 Md昆虫活性蛋白中间体的提取方法
CN104884068A (zh) * 2012-07-27 2015-09-02 株式会社爱南自由 多醣类、含有多醣类的组合物、以及免疫赋活剂
EP3578052A1 (fr) * 2018-06-05 2019-12-11 Bühler Insect Technology Solutions AG Traitement de larves d'insectes

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4998999B2 (ja) * 2007-09-11 2012-08-15 国立大学法人 岡山大学 ウジムシ治療用のカバードレッシング
KR101808028B1 (ko) 2016-08-10 2017-12-12 대한민국(농촌진흥청장) 습식분쇄법 및 분무건조법을 이용한 갈색거저리 유충의 분말 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913730A (ja) * 1982-07-15 1984-01-24 Wakunaga Seiyaku Kk 抗菌性蛋白、その製造法およびその用途
EP0284965A2 (fr) * 1987-03-30 1988-10-05 Sanwa Kagaku Kenkyusho Co., Ltd. Polypeptide antibactérien
US4960756A (en) * 1986-09-13 1990-10-02 Sanwa Kagaku Kenkyusho Co., Ltd. Lectin like protein substance, method of obtaining same and anti-tumor agent comprising same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913730A (ja) * 1982-07-15 1984-01-24 Wakunaga Seiyaku Kk 抗菌性蛋白、その製造法およびその用途
US4960756A (en) * 1986-09-13 1990-10-02 Sanwa Kagaku Kenkyusho Co., Ltd. Lectin like protein substance, method of obtaining same and anti-tumor agent comprising same
EP0284965A2 (fr) * 1987-03-30 1988-10-05 Sanwa Kagaku Kenkyusho Co., Ltd. Polypeptide antibactérien

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CONSTABLE S A: "A COMPARISON OF PROTEASES PRODUCED BY LARVAE OF LUCILIA CUPRINA (WIEDEMANN), L SERICATA (MEIGEN), CALLIPHORA AUGUR (F) AND C STYGIA(F) (DIPTERA: CALLIPHORIDAE)", AUSTRALIAN JOURNAL OF ENTOMOLOGY, AUSTRALIAN ENTOMOLOGICAL SOCIETY, CANBERRA,, AU, vol. 33, no. 3, 1994, pages 203 - 210, XP000980193, ISSN: 1326-6756 *
F. M BARRETT: "Purification of Phenolic Compounds and a Phenoloxidase from larval Cuticle of th red-humped Oakworm "Symmerista-Cannicosta"", ARCHIVES OF INSECT BIOCHEMISTRY AND PHYSIOLOGY, vol. 1, no. 3, 1984, pages 213 - 224, XP009002636 *
PATENT ABSTRACTS OF JAPAN vol. 008, no. 098 (C - 221) 9 May 1984 (1984-05-09) *
SANDEMAN R M ET AL: "TRYPTIC AND CHYMOTRYPTIC PROTEASES RELEASED BY LARVAE OF THE BLOWFLY, LUCILIA CUPRINA", INTERNATIONAL JOURNAL OF PARASITOLOGY, PERGAMON PRESS, GB, vol. 20, no. 8, 1990, pages 1019 - 1023, XP000978819, ISSN: 0020-7519 *
YOUNG A R ET AL: "CHARACTERIZATION OF ES PRODUCTS INVOLVED IN WOUND INITIATION BY LUCILIA CUPRINA LARVAE", INTERNATIONAL JOURNAL OF PARASITOLOGY, PERGAMON PRESS, GB, vol. 26, no. 3, 1996, pages 245 - 252, XP000978826, ISSN: 0020-7519 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075654A2 (fr) * 2002-03-09 2003-09-18 The Secretary Of State For Defence Traitement de surfaces peuplees de bacteries
WO2003075654A3 (fr) * 2002-03-09 2004-03-25 Univ Nottingham Traitement de surfaces peuplees de bacteries
GB2401788A (en) * 2002-03-09 2004-11-24 Secr Defence Treatment of surfaces populated by bacteria with a lucilia sericata extract
GB2401788B (en) * 2002-03-09 2006-10-18 Secr Defence Treatment of surfaces populated by bacteria
DE102005061246A1 (de) * 2005-12-20 2007-06-28 Alpha-Biocare Gmbh Präparate mit niedermolekularen Substanzen aus Dipteren zur Behandlung von Wunden
WO2007071540A1 (fr) * 2005-12-20 2007-06-28 Alpha-Biocare Gmbh Composition favorisant la cicatrisation des plaies comprenant des substances provenant de larves de dipteres
CN102008003A (zh) * 2010-12-14 2011-04-13 韦秀凤 Md昆虫活性蛋白中间体的提取方法
CN104884068A (zh) * 2012-07-27 2015-09-02 株式会社爱南自由 多醣类、含有多醣类的组合物、以及免疫赋活剂
EP3578052A1 (fr) * 2018-06-05 2019-12-11 Bühler Insect Technology Solutions AG Traitement de larves d'insectes
WO2019234106A1 (fr) * 2018-06-05 2019-12-12 Bühler Insect Technology Solutions Ag Traitement de larves d'insectes
RU2768025C1 (ru) * 2018-06-05 2022-03-23 Бюлер Инсект Текнолоджи Солюшнз Аг Переработка личинок насекомых
US11930803B2 (en) 2018-06-05 2024-03-19 Bühler AG Processing of insect larvae

Also Published As

Publication number Publication date
WO2003013557A8 (fr) 2004-02-26
JP2005501078A (ja) 2005-01-13
IL160274A0 (en) 2004-07-25
CA2456814A1 (fr) 2003-02-20
EP1434591A1 (fr) 2004-07-07
MXPA04000298A (es) 2004-05-04

Similar Documents

Publication Publication Date Title
RU2308954C2 (ru) Фармацевтическая композиция для лечения ран, содержащая плазму или сыворотку крови
DE69937562T2 (de) Verbessertes angereichertes blutplättchen wundheilmittel
Knottenbelt Equine wound management: are there significant differences in healing at different sites on the body?
DE69902234T2 (de) Matrixprotein enthaltende zusammensetzungen zur wundheilung
EP2869854A1 (fr) Composition contenant, en tant que principe actif, de l'ectoïne ou de l'hydroxyectoïne pour la reconstruction de tissus corporels lésés
KR20040111355A (ko) 미분화 태아 세포를 포함하는 피부 질환 치료용 조성물
Thomas Medicinal use of terrestrial molluscs (slugs and snails) with particular reference to their role in the treatment of wounds and other skin lesions
DE69328228T2 (de) Wundheilmittel
US20030124199A1 (en) Use of fly larval extracts for wound treatment
EP1965815B1 (fr) Composition favorisant la cicatrisation des plaies comprenant des substances provenant de larves de dipteres
WO2003013557A1 (fr) Utilisation d'extraits de larves de mouches pour traiter des plaies
DE60007973T2 (de) Matrixprotein zusammensetzungen für pfropfung in nicht mineralisierten geweben
DE10138303A1 (de) Verwendung von Enzymisolaten aus Fliegenlarven zur Wundbehandlung
DE10221194B4 (de) Hyaluronidasehaltiges Hautpflegemittel
DE60008077T2 (de) Matrixproteinzusammensetzungen um Apoptose zu induzieren
EP1827465B1 (fr) Preparations a base de chrysalides de dipteres destinees a traiter des blessures
DE10149153A1 (de) Verwendung von Enzymisolaten aus Fliegenlarven zur Wundbehandlung
Ali et al. Cod liver oil/honey mixture: an effective treatment of equine complicated lower leg wounds.
DE10327489B4 (de) Verwendung von Bestandteilen von Dipteren-Puppen zur Behandlung von Wunden
DE60222633T2 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
RU2337702C2 (ru) Бальзам "гайсановой", обладающий ранозаживляющим, противовоспалительным и противоожоговым действием
RU2063237C1 (ru) Ранозаживляющее средство
SHAIKH et al. Traditional remedies for wound healing: a review
DE102013111322A1 (de) Verfahren zur Herstellung von Hydrokolloid-Schwämmen
BR112013019417A2 (pt) composições para o debridamento, granulação e reepitelização de ferimentos em seres humanos

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000298

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002794527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 160274

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003518564

Country of ref document: JP

Ref document number: 2002333288

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2456814

Country of ref document: CA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 08/2003 UNDER (72) ADD "STEGE, HELGER; MARIE-JUCHACZ-WEG 41, 79111 FREIBURG (DE)."

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002794527

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002794527

Country of ref document: EP